Novartis AG Form 6-K Summary: Nine Months Ended September 30, 2002
Business Context and Reporting Period
This Form 6-K, dated October 17, 2002, reports the unaudited consolidated financial results for Novartis AG for the nine-month period ended September 30, 2002. Novartis is a global leader in pharmaceuticals and consumer health, headquartered in Basel, Switzerland. The report highlights a strategic shift to report financial results in US dollars starting in the first quarter of 2003 to better reflect performance and mitigate currency volatility, given that 43% of sales are generated in the US.
Key Financial Metrics
| Metric | Nine Months 2002 (CHF m) | Nine Months 2001 (CHF m) | Change (CHF) | Change (Local Currencies) |
|---|---|---|---|---|
| Sales | 24,247 | 23,384 | 4% | 11% |
| Operating Income | 5,919 | 5,353 | 11% | 13% |
| Operating Margin | 24.4% | 22.9% | +1.5 percentage points | |
| Net Income | 5,603 | 5,412 | 4% | N/A |
| Earnings Per Share (CHF) | 2.22 | 2.10 | 6% | N/A |
| Free Cash Flow | 2,009 | 2,323 | -14% | N/A |
| Net Liquidity | 7,998 | 8,103 | -1% | N/A |
| Debt-to-Equity Ratio | 0.19:1 | 0.21:1 | Improved | N/A |
Note: USD figures are convenience translations at a rate of 1.58 CHF/USD.
Material Changes vs. Prior Period
- Sales Growth: Group sales rose 11% in local currencies, driven by volume increases in Pharmaceuticals (+13% local currency) and Generics (+24% local currency). This growth offset a 7 percentage point negative currency impact due to the strong Swiss franc.
- Profitability: Operating income grew 11% in CHF, supported by productivity gains and a favorable product mix. Net income increased 4% despite lower net financial income compared to the prior year's record levels.
- Divisional Performance:
- Pharmaceuticals: Strong growth in cardiovascular (Diovan, Lotrel) and oncology (Gleevec, Zometa) franchises.
- Generics: Operating income soared 40% due to top-line growth and margin expansion.
- Consumer Health: Mixed results; Infant & Baby and CIBA Vision grew in local currencies, while OTC sales remained flat in local currencies.
- Balance Sheet: Equity decreased by CHF 4.0 billion due to share buybacks (CHF 5.2 billion), dividends, and translation losses, partially offset by net income. The debt-to-equity ratio improved.
Guidance, Outlook, and Risks
- Full-Year Outlook: Management expects good sales growth for the full year, driven by Pharmaceuticals. The Group anticipates meeting its target of approximately 10% sales growth in local currencies for the Pharmaceuticals division.
- Currency Impact: The sustained strength of the Swiss franc against the US dollar and Japanese yen is expected to significantly impact full-year results, though transactional exposures are fully hedged.
- Financial Income: Net financial income is expected to be slightly lower than the previous year's record level.
- Acquisitions and Divestitures:
- Acquisition: A friendly takeover bid for Lek (Slovenia) was announced with an offer expiring October 28, 2002.
- Divestiture: The sale of the Food & Beverage business (including Ovaltine) to Associated British Foods for approximately CHF 400 million is expected to close before year-end.
- Risks: Forward-looking statements are subject to risks including clinical trial uncertainties, regulatory delays, intellectual property protection, and government pricing pressures.
Key Facts for Investor Verification
- Currency Translation: Verify the impact of the strong Swiss franc on reported CHF figures versus local currency growth, noting the planned switch to USD reporting in 2003.
- Share Repurchases: Confirm the status of the third share buy-back program (up to CHF 4 billion), with CHF 1.4 billion utilized as of September 30, 2002.
- Product Pipeline: Monitor the commercial performance of new launches (Elidel, Zelnorm, Zometa) and the reimbursement status of key oncology drugs (Gleevec).
- Accounting Restatements: Note that 2001 sales were restated to reflect a change in the classification of sales incentives, reducing prior year sales by CHF 300 million.
- US GAAP Reconciliation: Review the significant differences between IAS and US GAAP net income (CHF 5.6 billion vs. CHF 4.6 billion) due to purchase accounting and pension provisions.